Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Christopher Parker; Nicholas D. James; Chris Brawley; Noel W. Clarke; Alex Hoyle; Adnan Ali; A.W.S. Ritchie; Gerhardt Attard; Simon Chowdhury; William Cross; David P. Dearnaley; Silke Gillessen; Clare Gilson; Robert J. Jones; Ruth E. Langley; Zafar Malik; Malcolm D. Mason; David Matheson; Robin Millman; John M. Russell; George N. Thalmann; Claire Amos; Roberto Alonzi; Amit Bahl; Alison Birtle; Omar Din; Hassan Douis; Chinnamani Eswar; Joanna Gale; Melissa Gannon; Sai Jonnada; Sara Khaksar; J.F. Lester; Joe M. O’Sullivan; Omi Parikh; Ian Pedley; Delia Pudney; D.J. Sheehan; Narayanan Srihari; Anna Tran; Mahesh Parmar; Matthew R. Sydes

doi:10.1016/s0140-6736(18)32486-3

Abstract

This is the authors' abstract. We don't add key points for this paper.

Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Astellas, Clovis Oncology, Janssen, Novartis, Pfizer, and Sanofi-Aventis.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Parker et al. (2018) studied this question.

synapsesocial.com/papers/69d73733779571b57e48f6a1 https://doi.org/10.1016/s0140-6736(18)32486-3

View Full Paper

Ask AI

Bookmark

Share

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Abstract

Ask about this paper

Discussion

Cite This Study

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading